Human parvovirus B19 and blood product safety: A tale of twenty years of improvements

Blood Transfusion

Volumn 13, Issue 2, 2015, Pages 184-196

  Marano, Giuseppe ^a   Vaglio, Stefania ^a,b   Pupella, Simonetta ^a   Facco, Giuseppina ^a,c   Calizzani, Gabriele ^a   Candura, Fabio ^a   Liumbruno, Giancarlo M ^a   Grazzini, Giuliano ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Joint Hospital University Institution Città della Salute e della Scienza   (Italy)

Author keywords

Blood product safety; Parvovirus B19; Parvovirus B19 prevalence; Plasma derived medicinal product; Transfusion transmitted parvovirus B19

Indexed keywords

ANTIVIRUS AGENT; IMMUNOGLOBULIN A ANTIBODY; VACCINE;

AUTOIMMUNE HEPATITIS; BLOOD; BLOOD DONOR; BLOOD PRODUCT SAFETY; BLOOD TRANSFUSION; BOCAPARVOVIRUS; BRAIN DISEASE; CLINICAL FEATURE; CONGESTIVE CARDIOMYOPATHY; DNA SCREENING; DONOR SELECTION; EPILEPSY; ERYTHEMA INFECTIOSUM; ERYTHROCYTE TRANSFUSION; FETUS WASTAGE; HUMAN; HUMAN PARVOVIRUS B19; IMMUNOTHERAPY; MENINGITIS; MYOCARDITIS; NONHUMAN; PARVOVIRIDAE; PARVOVIRUS 4; PERSISTENT INFECTION; POLYARTHRITIS; PREVALENCE; RASH; REVIEW; SAFETY; VIRAL CONTAMINATION; VIRUS LOAD; VIRUS TRANSMISSION; BLOOD COMPONENT THERAPY; BLOOD SAFETY; BLOODBORNE BACTERIUM;

BLOOD COMPONENT TRANSFUSION; BLOOD SAFETY; BLOOD-BORNE PATHOGENS; ERYTHEMA INFECTIOSUM; HUMANS; PARVOVIRUS B19, HUMAN;

EID: 84927513234     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2014.0174.14     Document Type: Review

References (159)

1. Pupella S, Pisani G, Cristiano K, et al. West Nile virus in the transfusion setting with a special focus on Italian preventive measures adopted in 2008-2012 and their impact on blood safety. Blood Transfus 2013;11:563-74.
2. Grazzini G, Liumbruno GM, Pupella S, et al. West Nile virus in Italy: a further threat to blood safety, a further challenge to the blood system. Blood Transfus 2008;6:235-7.
3. Liumbruno GM, Calteri D, Petropulacos K, et al. The chikungunya epidemic in Italy and its repercussion on the blood system. Blood Transfus 2008;6:199-210.
4. Lobo CA, Cursino-Santos JR, Alhassan A, Rodrigues M. Babesia: an emerging infectious threat in transfusion. PLoS Pathog 2013;9:e1003387.
5. Teo D, Ng LC, Lam S. Is dengue a threat to the blood supply? Transfus Med 2009;19:66-77.
6. Marano G, Vaglio S, Pupella S, et al. Hepatitis E: an old infection with new implications. Blood Transfus 2014; doi: 10.2450/2014.0063-14
7. Calizzani G, Vaglio S, Vetrugno V, et al. Management of notifications of donors with Creutzfeldt-Jakob disease (postdonation information). Blood Transfus 2014;12:22-7.
8. Dodd RY. B19: benign or not? Transfusion 2011;51:1878-9.
9. Alter HJ, Stramer SL, Dodd RY. Emerging infectious diseases that threaten the blood supply. Semin Hematol 2007;44:32-41.
10. Cotmore SF, Agbandje-McKenna M, Chiorini JA, et al. The family Parvoviridae. Arch Virol 2014;159:1239-47.
11. Cossart YE, Field AM, Cant B, Widdows D. Parvovirus-like particles in human sera. Lancet 1975;1:72-3.
12. Norja P, Lassila R, Makris M. Parvovirus transmission by blood products - a cause for concern? B J Haematol 2012;159:385-93.
13. Blümel J, Burger R, Drosten C, et al. Parvovirus B19 - revised. Transfus Med Hemother 2010;37:339-50.
14. Koppelman MH, Rood IG, Fryer JF, et al. Parvovirus B19 genotype 1 and 2 detection with real-time polymerase chain reaction assays. Vox Sang 2007;93:208-15.
15. Baylis SA. Standardization of nucleic acid amplification technique (NAT)-based assays for different genotypes of parvovirus B19: a meeting summary. Vox Sang 2008;94:74-80.
16. Candotti D, Etiz N, Parsyan A, Allain JP. Identification and characterization of persistent human erythrovirus infection in blood donor samples. J Virol 2004;78:12169-78.
17. Hübschen JM, Mihneva Z, Mentis AF, et al. Phylogenetic analysis of human parvovirus B19 sequences from eleven different countries confirms the predominance of genotype 1 and suggests the spread of genotype 3b. J Clin Microbiol 2009;47:3735-8.
18. Brown KE, Anderson SM, Young NS. Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science 1993;262:114-7.
19. Weigel-Kelley KA, Yoder MC, Srivastava A. Recombinant human parvovirus B19 vectors: erythrocyte P antigen is necessary but not sufficient for successful transduction of human hematopoietic cells. J Virol 2001;75:4110-6.
20. Brown KE, Hibbs JR, Gallinella G, et al. Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). N Engl J Med 1994;330:1192-6.
21. Yaegashi N, Shiraishi H, Takeshita T, et al. Propagation of human parvovirus B19 in primary culture of erythroid lineage cells derived from fetal liver. J Virol 1989;63:2422-6.
22. Schwarz TF, Serke S, Hottentrager B, et al. Replication of parvovirus B19 in hematopoietic progenitor cells generated in vitro from normal human peripheral blood. J Virol 1992;66:1273-6.
23. Srivastava CH, Zhou S, Munshi NC, et al. Parvovirus B19 replication in human umbilical cord blood cells. Virology 1992;189:456-61.
24. Takahashi T, Ozawa K, Takahashi K, et al. Susceptibility of human erythropoeitic cells to B19 parvovirus in vitro increases with differentiation. Blood 1990;75:603-10.
25. Corcoran A, Doyle S. Advances in the biology, diagnosis and host-pathogen interactions of parvovirus B19. J Med Microbiol 2004;53:459-75.
26. Erdman DD, Usher MJ, Tsou C, et al. Human parvovirus B19 specific IgG, IgA, and IgM antibodies and DNA in serum specimens from persons with erythema infectiosum. J Med Virol 1991;35:110-5.
27. Bluth MH, Norowitz KB, Chice S, et al. Detection of IgE anti parvovirus B19 and increased CD23+ B cells in parvovirus B19 infection: relation to Th2 cytokines. Clin Immunol 2003;108:152-8.
28. Anderson LJ, Tsou C, Parker RA, et al. Detection of antibodies and antigens of human parvovirus B19 by enzyme-linked immunosorbent assay. J Clin Microbiol 1986;24:522-6.
29. Kühl U, Pauschinger M, Noutsias M, et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with "idiopathic" left ventricular dysfunction. Circulation 2005;111:887-93;
30. Mouthon L, Guillevin L, Tellier Z. Intravenous immunoglobulins in autoimmune- or parvovirus B19-mediated pure red-cell aplasia. Autoimmun Rev 2005;4:264-9.
31. Bredl S, Plentz A, Wenzel JJ, et al. False-negative serology in patients with acute parvovirus B19 infection. J Clin Virol 2011;51:115-20.
32. Cassinotti P, Siegl, G. Quantitative evidence for persistence of human parvovirus B19 DNA in an immunocompetent individual. Eur J Clin Microbiol Infect Dis 2000;19:886-7.
33. Baylis SA, Shah N, Minor PD. Evaluation of different assays for the detection of parvovirus B19 DNA in human plasma. J Virol Methods 2004;121:7-16.
34. Servey JT, Reamy BV, Hodge J. Clinical presentations of parvovirus B19 infection. Am Fam Physician 2007;75:373-7.
35. van Beers-Tas MH, Heidema J. Pathogenesis of parvovirus infections in children. Virol Mycol 2013;2:1.
36. Heegaard ED, Brown KE. Human parvovirus B19. Clin Microbiol Rev 2002;15:485-505.
37. Exindari M, Chatzidimitriou D, Melidou A, et al. Epidemiological and clinical characteristics of human parvovirus B19 infections during 2006-2009 in Northern Greece. Hippokratia 2011;15:157-60.
38. Kurtzman GJ, Ozawa K, Cohen B, et al. Chronic bone marrow failure due to persistent B19 parvovirus infection. N Engl J Med 1987;317:287-94.
39. Liumbruno GM, Bennardello F, Lattanzio A, et al. Recommendations for the transfusion of red blood cells. Blood Transfus 2009;7:49-64.
40. Brown KE. The expanding range of parvoviruses which infect humans. Rev Med Virol 2010;20:231-44.
41. Puccetti C, Contoli M, Bonvicini F, et al. Parvovirus B19 in pregnancy: possible consequences of vertical transmission. Prenatal Diagnosis 2012;32:897-902.
42. Eid AJ, Chen SF; AST Infectious Diseases Community of Practice. Human parvovirus B19 in solid organ transplantation. Am J Transplant 2013;13(Suppl 4):201-5.
43. Heegaard ED, Laub Petersen B. Parvovirus B19 transmitted by bone marrow. Br J Haematol 2000;111:659-61.
44. Carraturo A, Catalani V, Ottaviani D, et al. Parvovirus B19 infection and severe anemia in renal transplant recipients. Scientific World Journal 2012;2012:102829.
45. Rahiala J, Koskenvuo M, Norja P, et al. Human parvoviruses B19, PARV4 and bocavirus in pediatric patients with allogeneic hematopoietic SCT. Bone Marrow Transplant 2013;48:1308-12.
46. Siegl G, Cassinotti P. Presence and significance of parvovirus B19 in blood and blood products. Biologicals 1998;26:89-94.
47. Satake M, Hoshi Y, Taira R, et al. Symptomatic parvovirus B19 infection caused by blood component transfusion. Transfusion 2011;51:1887-95.
48. Eis-Hubinger AM, Sasowski U, Brackmann HH. Parvovirus B19 DNA contamination in coagulation factor VIII products. Thromb Haemost 1999;81:476-7.
49. Laub R, Strengers P. Parvoviruses and blood products. Pathol Biol 2002;50:339-48.
50. Plentz A, Hahn J, Knöll A, et al. Exposure of hematologic patients to parvovirus B19 as a contaminant of blood cell preparations and blood products. Transfusion 2005;45:1811-5.
51. Schmidt M, Themann A, Drexler C, et al. Blood donor screening for parvovirus B19 in Germany and Austria. Transfusion 2007;47:1775-82.
52. Willkommen H, Schmidt I, Lower J. Safety issues for plasma derivatives and benefit from NAT testing. Biologicals 1999;27:325-31.
53. Koenigbauer UF, Eastlund T, Day JW. Clinical illness due to parvovirus B19 infection after infusion of solvent/detergenttreated pooled plasma. Transfusion 2000;40:1203-6.
54. Liumbruno GM, Franchini M. Solvent/detergent plasma: pharmaceutical characteristics and clinical experience. J Thromb Thrombolysis 2015;39;118-28.
55. Burnouf-Radosevich M, Appourchaux P, Huart JJ, et al. Nanofiltration, a new specific virus elimination method applied to high-purity factor IX and factor XI concentrates. Vox Sang 1994;67:132-8.
56. Azzi A, Morfini M, Mannucci PM. The transfusionassociated transmission of parvovirus B19 Transfus Med Rev 1999;13:194-204.
57. Yee TT, Cohen BJ, Pasi KJ, Lee CA. Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate. Br J Haematol 1996;93:457-9.
58. Lefrère JJ, Mariotti M. Use of digoxigenin-labelled probes for the detection of B19 parvovirus DNA in batches of blood products. Cell Mol Biol 1995;41:985-8.
59. Lefrère JJ, Mariotti M, de la Croix I, et al. Albumin batches and B19 parvovirus DNA. Transfusion 1995;35:389-91.
60. Lefrere JJ, Mariotti M, Thauvin M. B19 parvovirus DNA in solvent/detergent-treated anti-haemophilia concentrates. Lancet 1994, 343: 211-2.
61. Rollag H, Solheim BG, Svennevig JL. Viral safety of blood derivatives by immune neutralization. Vox Sang 1998;74:213-7.
62. Saldanha J, Minor P. Detection of human parvovirus B19 DNA in plasma pools and blood products derived from these pools: implications for efficiency and consistency of removal of B19 DNA during manufacture. Br J Haematol 1996;93:714-9.
63. Corcioli F, Zakrzewska K, Fanci R, et al. Human parvovirus PARV4 DNA in tissues from adult individuals: a comparison with human parvovirus B19 (B19V). Virol J 2010;7:272.
64. Geng Y, Wu C-G, Bhattacharyya SP, et al. Parvovirus B19 DNA in factor VIII concentrates: effects of manufacturing procedures and B19 screening by nucleic acid testing. Transfusion 2007;47:883-9.
65. Modrow S, Wenzel JJ, Schimanski S, et al. Prevalence of nucleic acid sequences specific for human parvoviruses, hepatitis A and hepatitis E viruses in coagulation factor concentrates. Vox Sang 2011;100:351-8.
66. Soucie JM, Monahan PE, Kulkarni R, et al. Evidence for the continued transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates. Transfusion 2013:53:1143-4.
67. Saldanha J. Validation and standardisation of nucleic acid amplification technology (NAT) assays for the detection of viral contamination of blood and blood products. J Clin Virol 2001;20:7-13.
68. Kleinman SH, Glynn SA, Lee TH, et al. National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study-II (NHLBI REDS-II). A linked donor-recipient study to evaluate parvovirus B19 transmission by blood component transfusion. Blood 2009;114:3677-83.
69. Klukowska A, Komrska V, Jansen M, Laguna P. Low incidence of factor VIII inhibitors in previously untreated patients during prophylaxis, on-demand treatment and surgical procedures, with Octanate®: interim report from an ongoing prospective clinical study. Haemophilia 2011;17:399-406.
70. Mundt JM, Rouse L, Van den Bossche J, Goodrich RP. Chemical and biological mechanisms of pathogen reduction technologies. Photochem Photobiol 2014, 90:957-64.
71. Goeyvaerts N, Hens N, Ogunjimi B, et al. Estimating infectious disease parameters from data on social contacts and serological status. J Royal Stat Soc 2010;13:255.
72. US Food and Drug Administration. Guidance for Industry: Nucleic Acid Testing (NAT) to Reduce the Possible Risk of Parvovirus B19 Transmission by Plasma-Derived Products; 2009. Available at: http://www.fda.gov/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/blood/ucm071592.htm. Accessed on 25/06/2014.
73. Council of Europe. Human plasma (pooled and treated for virus inactivation), monograph 1646. In: European Pharmacopoeia. 6th ed. Strasbourg: Council of Europe Publishing; 2008.
74. Hourfar MK, Mayr-Wohlfart U, Themann A, et al. Recipients potentially infected with parvovirus B19 by red blood cell products. Transfusion 2011;51:129-36.
75. Kooistra K, Mesman HJ, De Waal M, et al. Epidemiology of high-level parvovirus B19 viremia among Dutch blood donors, 2003-2009. Vox Sang 2010;100:261-6.
76. Jordan J, Tiangco B, Kiss J, et al. Human parvovirus B19: prevalence of viral DNA in volunteer blood donors and clinical outcomes of transfusion recipients. Vox Sang 1998;75:97-102.
77. Broliden K, Tolfvenstam T, Norbeck O. Clinical aspects of parvovirus B19 infection. J Internal Med 2006;260:285-304.
78. Petermann R, Piquet Y, Lapeyre M, et al. Detection of B19 parvovirus in plasma pools before solvent-detergent treatment of plasma: AFSSAPS and EFS Aquitaine-Limousin's experience. Transfus Clin Biol 2010;17:54-62 [In French].
79. Zhang W, Ke L, Changqing L, et al. Parvovirus B19V DNA contamination in Chinese plasma and plasma derivatives. J Transl Med 2012;10:194.
80. Kleinman SH, Glynn SA, Lee TH, et al. National Heart, Lung, Blood Institute Retrovirus Epidemiology Donor Study (REDS-II). Prevalence and quantitation of parvovirus B19 DNA levels in blood donors with a sensitive polymerase chain reaction screening assay. Transfusion 2007;47:1756-64.
81. Grabarczyk P, Korzeniowska J, Liszewski G et al. Parvovirus B19 DNA testing in Polish blood donors, 2004-2010. Przegl Epidemiol 2012;66:7-12.
82. Sakata H, Matsubayashi K, Ihara H, et al. Impact of chemiluminescent enzyme immunoassay screening for human parvovirus B19 antigen in Japanese blood donors. Transfusion 2013;53:2556-66.
83. Koppelman MH, Cuijpers HT, Wessberg S, et al. Multicenter evaluation of a commercial multiplex polymerase chain reaction test for screening plasma donations for parvovirus B19 DNA and hepatitis A virus RNA. Transfusion 2012;52:1498-508.
84. Weimer T, Streichert S, Watson C, Groner A. High-titer screening PCR: a successful strategy for reducing the parvovirus B19 load in plasma pools for fractionation. Transfusion 2001;41:1500-4.
85. Lefrere JJ, Servant-Delmas A, Candotti D, et al. Persistent B19 infection in immunocompetent individuals: implications for transfusion safety. Blood 2005;106:2890-5.
86. Compston LI, Sarkobie F, Li C, et al. Multiplex real-time PCR for the detection and quantification of latent and persistent viral genomes in cellular or plasma blood fractions. J Virol Methods 2008;151:47-54.
87. Wasfy S, Nishikawa J, Petric M. Seroprevalence of immunoglobulin G antibody to parvovirus B19 in Ontario. Can J Infect Dis 1996;7:313-6.
88. Slavov SN, Haddad SK, Silva-Pinto AC, et al. Molecular and phylogenetic analyses of human Parvovirus B19 isolated from Brazilian patients with sickle cell disease and β-thalassemia major and healthy blood donors. J Med Virol 2012;84:1652-65.
89. Slavov SN, Kashima S, Silva-Pinto AC, Covas DT. Genotyping of Human parvovirus B19 among Brazilian patients with hemoglobinopathies. Can J Microbiol 2012;58:200-5.
90. Levican J, Torres M, Gaggero N, et al. Parvovirus B19 among blood donors from three hospitals in Santiago, Chile. Rev Med Chil 2011;139:143-9.
91. Gaggero A, Rivera J, Calquin E, et al. Seroprevalence of IgG antibodies against parvovirus B19 among blood donors from Santiago, Chile. Rev Med Chil 2007;135:443-8.
92. O'Bryan TA, Wright WF. Parvovirus B19 and C-reactive protein in blood bank donors: implications for hygiene hypothesis research. Lupus 2010;19:1557-60.
93. Doyle S, Kerr S, O'Keeffe G, et al. Detection of parvovirus B19 IgM by antibody capture enzyme immunoassay: receiver operating characteristic analysis. J Virol Methods 2000;90:143-52.
94. Ke L, He M, Li C, et al. The prevalence of human parvovirus B19 DNA and antibodies in blood donors from four Chinese blood centers. Transfusion 2011;51:1909-18.
95. Wei Q, Li Y, Wang JW, et al. Prevalence of anti-human parvovirus B19 IgG antibody among blood donors in Jilin province. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2006;20:60-2.
96. Kumar S, Gupta RM, Sen S, et al. Seroprevalence of human parvovirus B19 in healthy blood donors. Med J Armed Forces India 2013;69:268-72.
97. Kishore J, Srivastava M, Choudhary N. Standardization of B19 IgG ELISA to study the seroepidemiology of parvovirus B19 in North Indian voluntary blood donors. Asian J Transfus Sci 2010;4:86-90.
98. Ihara T, Furusyo N, Hayashi T, et al. A population-based epidemiological survey of human parvovirus B19 infection: a project of the Kyushu and Okinawa Population Study (KOPS). Arch Virol 2013;158:2465-72.
99. Matsukura H, Shibata S, Tani Y, et al. Persistent infection by human parvovirus B19 in qualified blood donors. Transfusion 2008;48:1036-7.
100. Wakamatsu C, Takakura F, Kojima E, et al. Screening of blood donors for human parvovirus B19 and characterization of the results. Vox Sang 1999;76:14-21.
101. Tsujimura M, Matsushita K, Shiraki H, et al. Human parvovirus B19 infection in blood donors. Vox Sang 1995;69:206-12.
102. Obeid OE. Molecular and serological assessment of parvovirus B19 infections among sickle cell anemia patients. J Infect Dev Ctries 2011;5:535-9.
103. Oh DJ, Lee YL, Kang JW, et al. Investigation of the prevalence of human parvovirus B19 DNA in Korean plasmapheresis donors. Korean J Lab Med 2010;30:58-64.
104. Poovorawan Y, Theamboonlers A, Suandork P, Hirsch P. Prevalence of antibodies to parvovirus B 19 in Thailand. Southeast Asian J Trop Med Public Health 2000;31:422-4.
105. Thomas I, Di Giambattista M, Gerard C, et al. Prevalence of human erythrovirus B19 DNA in healthy Belgian blood donors and correlation with specific antibodies against structural and non-structural viral proteins. Vox Sang 2003;84:300-7.
106. Hitzler WE, Runkel S. Prevalence of human parvovirus B19 in blood donors as determined by a haemagglutination assay and verified by the polymerase chain reaction. Vox Sang 2002;82:18-23.
107. Juhl D, Steppat D, Gorg S, Hennig H. Parvovirus b19 infections and blood counts in blood donors. Transfus Med Hemother 2014;41:52-9.
108. Kooistra K, Mesman HJ, de Waal M, et al. Epidemiology of high-level parvovirus B19 viraemia among Dutch blood donors, 2003-2009. Vox Sang 2011;100:261-6.
109. Corcoran A, Kerr S, Elliott G, et al. Improved detection of acute parvovirus B19 infection by immunoglobulin M EIA in combination with a novel antigen EIA. Vox Sang 2007;93:216-22
110. Zaaijer HL, Koppelman MH, Farrington CP. Parvovirus B19 viraemia in Dutch blood donors. Epidemiol Infect 2004;132:1161-6.
111. Gessoni G, Barin P, Di Natale C, Marchiori G. NAT screening for Parvovirus B19: a feasibility study. Blood Transfus 2006;4:67-80.
112. Manaresi E, Gallinella G, Morselli Labate AM, et al. Seroprevalence of IgG against conformational and linear capsid antigens of parvovirus B19 in Italian blood donors. Epidemiol Infect 2004;132:857-62.
113. Henriques I, Monteiro F, Meireles E, et al. Prevalence of parvovirus B19 and hepatitis A virus in Portuguese blood donors. Transfus Apher Sci 2005;33:305-9.
114. Filatova EV, Zubkova NV, Novikova NA, et al. Detection of parvovirus B19 markers in blood samples of donors. Zh Mikrobiol Epidemiol Immunobiol 2010;5:67-70.
115. Munoz S, Alonso MA, Fernandez MJ, et al. Seroprevalence versus Parvovirus B19 in blood donors. Enferm Infecc Microbiol Clin 1998;16:161-2.
116. Mata Rebon M, Bartolome Husson C, Bernardez Hermida I. Seroprevalence of anti-human parvovirus B19 antibodies in a sample of blood donors in Galicia. Enferm Infecc Microbiol Clin 1998;16:25-7.
117. Letaief M, Vanham G, Boukef K, et al. Higher prevalence of parvovirus B19 in Belgian as compared to Tunisian blood donors: differential implications for prevention of transfusional transmission. Transfus Sci 1997;18:523-30.
118. Reinheimer C, Allwinn R, Doerr HW, Wittek M. Seroepidemiology of parvovirus B19 in the Frankfurt am Main area, Germany: evaluation of risk factors. Infection 2010;38:381-5.
119. Langara H, Trikia H, Gouiderb E, et al. Blood-transmitted viral infections among haemophiliacs in Tunisia. Transfus Clin Biol 2005;12:301-5 [In French].
120. Soucie JM, Siwak EB, Hooper WC, et al.; Universal Data Collection Project Working Group. Human parvovirus B19 in young male patients with hemophilia A: associations with treatment product exposure and joint range-of-motion limitation. Transfusion 2004;44:1179-85.
121. Brojer E, Grabarczyk P, Łopaciuk S, et al. Prevalence of human parvovirus B19 DNA and IgG/IgM antibodies in Polish haemophilia patients. Vox Sang 1999;77:107.
122. Canales MA, Pinilla J, Mateos P. Human parvovirus B19 antibodies are less frequent among patients treated with factor IX concentrate inactivated by ultrafiltration: a report from a single Spanish institution. Vox Sang 1998;74:260-1.
123. Mauser-Bunschoten EP, Zaaijer HL, van Drimmelen AA. High prevalence of Parvovirus B19 lgG antibodies among Dutch hemophilia patients. Vox Sang 1998;74:225-7.
124. Aguilar Franco C, Lucia Cuesta JF, Ferrer Torres J, Omenaca Teres M. Parvovirus B19 infection in patients with congenital blood coagulation disorders. Med Clin (Barc) 1997;108:641-6.
125. Erratum in: Med Clin (Barc) 1997;109:5 [In Spanish].
126. Ragni MV, Koch WC, Jordan JA. Parvovirus B19 infection in patients with hemophilia. Transfusion 1996;36:238-41.
127. Zakrzewska K, Azzi A, De Biasi E, et al. Persistence of parvovirus B19 DNA in synovium of patients with haemophilic arthritis. J Med Virol 2001;65:402-7.
128. Bartolomei Corsi O, Azzi A, Morfini M, et al. Human parvovirus infection in haemophiliacs first infused with treated clotting factor concentrates. J Med Virol 1988;25:165-70.
129. Manning A, Willey SJ, Bell JE, Simmonds P. Comparison of tissue distribution, persistence, and molecular epidemiology of parvovirus B19 and novel human parvoviruses PARV4 and human bocavirus. J Infect Dis 2007;195:1345-52.
130. Jones MS, Kapoor A, Lukashov VV, et al. New DNA viruses identified in patients with acute viral infection syndrome. J Virol 2005;79:8230-6.
131. Fryer JF, Delwart E, Hecht FM, et al. Frequent detection of the parvoviruses, PARV4 and PARV5, in plasma from blood donors and symptomatic individuals. Transfusion 2007;47:1054-61.
132. Simmonds P, Douglas J, Bestetti G, et al. A third genotype of the human parvovirus PARV4 in sub-Saharan Africa. J Gen Virol 2008;89:2299-302.
133. Drexler JF, Reber U, Muth D, et al. Human parvovirus 4 in nasal and fecal specimens from children, Ghana. Emerg Infect Dis 2012;18:1650-3.
134. Ma YY, Guo Y, Zhao X, et al. Human parvovirus PARV4 in plasma pools of Chinese origin. Vox Sang 2012;103:183-5.
135. Fryer JF, Hubbard AR, Baylis SA. Human parvovirus PARV4 in clotting factor VIII concentrates. Vox Sang 2007;93:341-7.
136. Schneider B, Fryer JF, Oldenburg J, et al. Frequency of contamination of coagulation factor concentrates with novel human parvovirus PARV4. Haemophilia 2008;14:978-86.
137. Eis-Hubinger AM, Drexler JF, Reber U, et al. Absence of detection of novel human parvoviruses in German plasma donations. Transfusion 2010;50:266-7.
138. Baylis SA, Tuke PW, Miyagawa E, Blumel J. Studies on the inactivation of human parvovirus 4. Transfusion 2013;53:2585-92.
139. Fryer JF, Lucas SB, Padley D, Baylis SA. Parvoviruses PARV4/5 in hepatitis C virus-infected persons. Emerg Infect Dis 2007;13:175-6.
140. Simmonds P, Manning A, Kenneil R, et al. Parenteral transmission of the novel human parvovirus PARV4. Emerg Infect Dis 2007;13:1386-8.
141. Longhi E, Bestetti G, Acquaviva V, et al. Human parvovirus 4 in the bone marrow of Italian patients with AIDS. AIDS 2007;21:1481-3.
142. Lurcharchaiwong W, Chieochansin T, Payungporn S, et al. Parvovirus 4 (PARV4) in serum of intravenous drug users and blood donors. Infection 2008;36:488-91.
143. Fryer JF, Kapoor A, Minor PD, et al. Novel parvovirus and related variant in human plasma. Emerg Infect Dis 2006;12:151-4.
144. Vallerini D, Barozzi P, Quadrelli C, et al. Parvoviruses in blood donors and transplant patients, Italy. Emerg Infect Dis 2008;14:185-6.
145. Botto S, Bergallo M, Sidoti F, et al. Detection of PARV4, genotypes 1 and 2, in healthy and pathological clinical specimens. New Microbiol 2009;32:189-92.
146. Servant-Delmas A, Laperche S, Mercier M, et al. Human parvovirus 4 in recipients of cellular products and in blood donors: epidemiologic similarity with B19 parvovirus. Transfusion 2009;49:1771-3.
147. Tuke PW, Parry RP, Appleton H. Parvovirus PARV4 visualization and detection. J Gen Virol 2010;91:541-4.
148. Panning M, Kobbe R, Vollbach S, et al. Novel human parvovirus 4 genotype 3 in infants, Ghana. Emerg Infect Dis 2010;16:1143-6.
149. Touinssi M, Brisbarre N, Picard C, et al. Parvovirus 4 in blood donors, France. Emerg Infect Dis 2010;16:165-6.
150. Touinssi M, Reynaud-Gaubert M, Gomez C, et al. Parvovirus 4 in French in-patients: a study of hemodialysis and lung transplant cohorts. J Med Virol 2011;83:717-20.
151. Maple PA, Beard S, Parry RP, et al. Testing UK blood donors for exposure to human parvovirus 4 using a time-resolved fluorescence immunoassay to screen sera and Western blot to confirm reactive samples. Transfusion 2013;53:2575-84.
152. Sharp CP, Lail A, Donfield S, et al. Virologic and clinical features of primary infection with human parvovirus 4 in subjects with hemophilia: frequent transmission by virally inactivated clotting factor concentrates. Transfusion 2012;52:1482-9.
153. Allander T, Tammi MT, Eriksson M, et al. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc Natl Acad Sci USA 2005;102:12891-96.
154. Jartti T, Hedman K, Jartti L, et al. Human bocavirus-the first 5 years. Rev Med Virol 2012;22:46-64.
155. Norja P, Hedman L, Kantola K, et al. Occurrence of human bocaviruses and parvovirus 4 in solid tissues. J Med Virol 2012;8:1267-73.
156. Kantola K, Hedman L, Arthur J, et al. Seroepidemiology of human bocaviruses 1-4. J Infect Dis 2011;204:1403-12.
157. Di Minno G, Canaro M, Ironside JW, et al. Pathogen safety of long-term treatments for bleeding disorders: still relevant to current practice. Haematologica 2013;98:1495-8.
158. Groeneveld K, van der Noordaa J. Blood products and parvovirus B19. Neth J Med 2003;61:154-6.
159. AABB Special Issue: Emerging Infectious Disease Agents and their Potential Threat to Transfusion Safety. Human Parvovirus B19. Transfusion 2009;49:107S-9S.